Brightlands Venture Partners portfolio firm Hy2Care joins MedTech Innovator 2026 accelerator cohort

  • Brightlands Venture Partners portfolio company Hy2Care was selected for MedTech Innovator’s 2026 Accelerator Cohort, a 65-company group.
  • Hy2Care ranked in the top 4% of 1,835 applicants, gaining visibility through the inaugural MTI Index 2026.
  • CartRevive, its injectable hydrogel implant for cartilage repair, completed first-in-human and European pivotal trials in 46 patients.
  • The company holds FDA Breakthrough Device designation, securing FDA IDE approval to advance US clinical development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brightlands Venture Partners BV published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.